Cite
HARVARD Citation
Mesa, R. et al. (2017). Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet. 4 (5), pp. e225-e236. [Online].